Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
株式のランク #30361
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
株価
$0.25620952
最終同期: 2024-07-23
時価総額
$17.14M
変化(1日)
10.83%
変化(1年)
0.00%
BE
取引 Mithra Pharmaceuticals S.A. (MITRA)

カテゴリー

Mithra Pharmaceuticals S.A.(MITRA)の配当利回りの履歴
Mithra Pharmaceuticals S.A.(銘柄コード: MITRA)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Mithra Pharmaceuticals S.A.(MITRA)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)